Molecular structure of Terazosin hydrochloride, CAS Number: 63074-08-8
Terazosin hydrochloride (CAS 63074-08-8)
Application:
Terazosin hydrochloride is an α1- and α2B-adrenoceptor antagonist
CAS Number:
63074-08-8
Purity:
≥98%
Molecular Weight:
423.9
Molecular Formula:
C19H25N5O4•HCl
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Terazosin hydrochloride acts as an α1- and α2B-adrenoceptor antagonist (Ki values are 3.3, 0.7, 1.1, 7.7, 1510 and 78.2 nM for α1A, α1B, α1D, α2B, α2A and α2C receptors respectively).
Terazosin hydrochloride (CAS 63074-08-8) References
- Transdermal drug delivery using electroporation. II. Factors influencing skin reversibility in electroporative delivery of terazosin hydrochloride in hairless rats. | Sharma, A., et al. 2000. J Pharm Sci. 89: 536-44. PMID: 10737915
- Bunazosin hydrochloride reduces glutamate-induced neurotoxicity in rat primary retinal cultures. | Goto, W., et al. 2004. Brain Res. 1003: 130-7. PMID: 15019572
- alpha1-Adrenergic mechanism in diabetic urethral dysfunction in rats. | Torimoto, K., et al. 2005. J Urol. 173: 1027-32. PMID: 15711370
- Identification, preparation, and characterization of several polymorphs and solvates of terazosin hydrochloride. | Bauer, J., et al. 2006. J Pharm Sci. 95: 917-28. PMID: 16493591
- Terazosin modifies the content of glycosaminoglycans and the activity of matrix metalloproteinase 2 in the rat ventral prostate. | Mitropoulos, D., et al. 2007. Eur Urol. 51: 447-56; discussion 456. PMID: 16899336
- Terazosin treatment suppresses basic fibroblast growth factor expression in the rat ventral prostate. | Mitropoulos, D., et al. 2009. Clin Invest Med. 32: E1-7. PMID: 19178873
- Terazosin-induced alterations in catalase expression and lipid peroxidation in the rat seminal vesicles. | Mitropoulos, D., et al. 2013. Andrologia. 45: 128-34. PMID: 22731390
- Terazosin treatment induces caspase-3 expression in the rat ventral prostate. | Papadopoulos, G., et al. 2013. J Clin Med Res. 5: 127-31. PMID: 23518907
- Thermoanalytical investigation of terazosin hydrochloride. | Attia, AK. and Mohamed Abdel-Moety, M. 2013. Adv Pharm Bull. 3: 147-52. PMID: 24312828
- Rayleigh light scattering detection of three α1-adrenoceptor antagonists coupled with high performance liquid chromatograph. | Li, AP., et al. 2015. Spectrochim Acta A Mol Biomol Spectrosc. 147: 178-84. PMID: 25840026
- Utility of Hantzsch reaction for development of highly sensitive spectrofluorimetric method for determination of alfuzosin and terazosin in bulk, dosage forms and human plasma. | Hammad, MA., et al. 2017. Luminescence. 32: 1066-1071. PMID: 28303653
- Magnetic-Dispersive Solid Phase Extraction Based on Graphene Oxide-Fe3O4 Nanocomposites Followed by High Performance Liquid Chromatography-Fluorescence for the Preconcentration and Determination of Terazosin Hydrochloride in Human Plasma. | Pashaei, Y., et al. 2020. J Chromatogr Sci. 58: 178-186. PMID: 31746326
- Mending the fluorescence of two α-blockers through a semiquinoid formation: Hyphenated with experimental design optimization. | Omar, MA., et al. 2020. Spectrochim Acta A Mol Biomol Spectrosc. 240: 118624. PMID: 32604051
- Terazosin blockade of nicotine-induced skin flap necrosis in the rat. | Karien, RG. and Maisel, RH. 1997. Arch Otolaryngol Head Neck Surg. 123: 837-40. PMID: 9260549
Activator of:
α1D-AR, alpha1A-AR, alpha1B-AR, and alpha2B-AR.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Terazosin hydrochloride, 50 mg | sc-204337 | 50 mg | $115.00 |